<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00309608</url>
  </required_header>
  <id_info>
    <org_study_id>1218.6</org_study_id>
    <secondary_id>2005-004597-24</secondary_id>
    <nct_id>NCT00309608</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Five Parallel Groups Study Investigating the Efficacy and Safety of BI 1356 BS (1 mg, 5 mg and 10 mg Administered Orally Once Daily) Over 12 Weeks as add-on Therapy in Patients With Type 2 Diabetes and Insufficient Glycaemic Control Despite Metformin Therapy, Including an Open-label Glimepiride Treatment Arm.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the study is to test the efficacy, safety and tolerability of several doses
      of BI 1356 BS (1, 5, or 10 mg taken once daily) compared to placebo given for 12 weeks
      together with metformin in patients with type 2 diabetes mellitus who are not at goal with
      their HbA1c levels. In addition, there will be an unblinded treatment arm with glimepiride as
      add-on therapy to metformin for comparison. The influence of several factors (gender, age,
      weight, race, etc.) on the bioavailability and efficacy of BI 1356 BS will also be tested in
      this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c Change From Baseline at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the HbA1c percent baseline value. Means are treatment adjusted for baseline HbA1c.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With HbA1c&lt;=7.0% at Week 12</measure>
    <time_frame>week 12</time_frame>
    <description>Descriptive calculation of Patients with HbA1c &lt;= 7.0% at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Plasma Glucose Level (FPG) Change From Baseline at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">333</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Linagliptin low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Linagliptin low dose tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Linagliptin medium dose tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Linagliptin high dose tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive tablets identical to those containing Linagliptin low, medium and high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive Glimepiride tablets once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Linagliptin medium dose tablet once daily</description>
    <arm_group_label>Linagliptin medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Linagliptin high dose tablet once daily</description>
    <arm_group_label>Linagliptin high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Linagliptin low dose tablet once daily</description>
    <arm_group_label>Linagliptin low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Glimepiride tablets once daily</description>
    <arm_group_label>Glimepiride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Inclusion_Criteria:

          -  Male and female patients with a diagnosis of type 2 diabetes mellitus and previo usly
             treated with metformin alone or with metformin and one other oral antidiabetic d rug

          -  HbA1c 7.0 9.0% at screening for patients treated with metformin and one other oral
             antidiabetic drug

          -  HbA1c 7.5 10.0% at screening for patients treated with metformin alone

          -  HbA1c 7.5 10.0% at beginning of the placebo run-in phase

          -  Age &gt; 21 and &lt; 75 years

          -  MI &gt; 25 and &lt; 40 kg/m2 (Body Mass Index)

        Exclusion criteria:

        Exclusion_Criteria:

          -  Clinically relevant cardiovascular disease

          -  Impaired hepatic function

          -  Renal insufficiency or impaired renal function

          -  Treatment with rosiglitazone or pioglitazone within 6 months prior to screening

          -  Treatment with insulin within 3 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1218.6.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joue les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.3305A Euraxi Pharma</name>
      <address>
        <city>Joue les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué Les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris cedex 13</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.49014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Immenstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuwied</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.49017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Offenbach a. M.</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saarbrücken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sinsheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Ingbert/Oberwürzbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.49015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sulzbach-Rosenberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.49016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.42103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.42104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.42105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.42101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nove Mesto nad Vahom</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uddevalla</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dnyepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.44012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ashford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.44004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baillieston, Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.44013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Camberley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.44016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chorley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gillingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.44015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.44008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.44017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.44018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.44009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.6.44019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Slovakia</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2006</study_first_submitted>
  <study_first_submitted_qc>March 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <results_first_submitted>May 13, 2011</results_first_submitted>
  <results_first_submitted_qc>May 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 15, 2011</results_first_posted>
  <last_update_submitted>June 24, 2014</last_update_submitted>
  <last_update_submitted_qc>June 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Patients randomized to receive treatment with matching placebo</description>
        </group>
        <group group_id="P2">
          <title>Linagliptin 1 mg</title>
          <description>Patients randomized to receive treatment with Linagliptin 1 mg</description>
        </group>
        <group group_id="P3">
          <title>Linagliptin 5 mg</title>
          <description>Patients randomized to receive treatment with Linagliptin 5 mg</description>
        </group>
        <group group_id="P4">
          <title>Linagliptin 10 mg</title>
          <description>Patients randomized to receive treatment with Linagliptin 10 mg</description>
        </group>
        <group group_id="P5">
          <title>Glimepiride</title>
          <description>Patients randomized to receive treatment with Glimepiride</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="66"/>
                <participants group_id="P4" count="66"/>
                <participants group_id="P5" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="56"/>
                <participants group_id="P4" count="60"/>
                <participants group_id="P5" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other incl. Lack of efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients randomized to receive treatment with matching placebo</description>
        </group>
        <group group_id="B2">
          <title>Linagliptin 1 mg</title>
          <description>Patients randomized to receive treatment with Linagliptin 1 mg</description>
        </group>
        <group group_id="B3">
          <title>Linagliptin 5 mg</title>
          <description>Patients randomized to receive treatment with Linagliptin 5 mg</description>
        </group>
        <group group_id="B4">
          <title>Linagliptin 10 mg</title>
          <description>Patients randomized to receive treatment with Linagliptin 10 mg</description>
        </group>
        <group group_id="B5">
          <title>Glimepiride</title>
          <description>Patients randomized to receive treatment with Glimepiride</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="66"/>
            <count group_id="B4" value="66"/>
            <count group_id="B5" value="65"/>
            <count group_id="B6" value="333"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.1" spread="8.1"/>
                    <measurement group_id="B2" value="59.2" spread="8.4"/>
                    <measurement group_id="B3" value="59.6" spread="9.8"/>
                    <measurement group_id="B4" value="61.8" spread="8.8"/>
                    <measurement group_id="B5" value="59.4" spread="9.9"/>
                    <measurement group_id="B6" value="60.0" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI) continuous</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" spread="4.2"/>
                    <measurement group_id="B2" value="32.3" spread="4.3"/>
                    <measurement group_id="B3" value="31.7" spread="4.5"/>
                    <measurement group_id="B4" value="31.7" spread="4.5"/>
                    <measurement group_id="B5" value="31.5" spread="4.2"/>
                    <measurement group_id="B6" value="31.9" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Hemoglobin A1 (HbA1C) continuous</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.37" spread="0.74"/>
                    <measurement group_id="B2" value="8.24" spread="0.74"/>
                    <measurement group_id="B3" value="8.46" spread="0.85"/>
                    <measurement group_id="B4" value="8.35" spread="0.73"/>
                    <measurement group_id="B5" value="8.22" spread="0.70"/>
                    <measurement group_id="B6" value="8.33" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose (FPG) continuous</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185.5" spread="38.8"/>
                    <measurement group_id="B2" value="182.3" spread="42.0"/>
                    <measurement group_id="B3" value="189.3" spread="42.4"/>
                    <measurement group_id="B4" value="188.7" spread="42.4"/>
                    <measurement group_id="B5" value="179.9" spread="40.4"/>
                    <measurement group_id="B6" value="185.1" spread="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HbA1c Change From Baseline at Week 12</title>
        <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the HbA1c percent baseline value. Means are treatment adjusted for baseline HbA1c.</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 1 mg</title>
            <description>Patients randomized to receive treatment with Linagliptin 1 mg</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin 5 mg</title>
            <description>Patients randomized to receive treatment with Linagliptin 5 mg</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin 10 mg</title>
            <description>Patients randomized to receive treatment with Linagliptin 10 mg</description>
          </group>
          <group group_id="O5">
            <title>Glimepiride</title>
            <description>Patients randomized to receive treatment with Glimepiride</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline at Week 12</title>
          <description>HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the HbA1c percent baseline value. Means are treatment adjusted for baseline HbA1c.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.10"/>
                    <measurement group_id="O2" value="-0.15" spread="0.10"/>
                    <measurement group_id="O3" value="-0.48" spread="0.11"/>
                    <measurement group_id="O4" value="-0.42" spread="0.10"/>
                    <measurement group_id="O5" value="-0.59" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 10 mg vs. Placebo
Missing endpoints after 12 weeks of treatment were replaced using &quot;Last Observation Carried Forward&quot; (LOCF)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>There was no adjustment for multiple testing, however a hierarchy approach to control for the Type-I error was used. If the 10mg was not successful, any analysis of the 5mg will be descriptive, and similarly for the next step for the 1mg.</p_value_desc>
            <method>Pairwise comparison based on ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.95</ci_lower_limit>
            <ci_upper_limit>-0.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5 mg vs. Placebo
missing endpoints after 12 weeks of treatment were replaced using &quot;Last Observation Carried Forward&quot; (LOCF)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>There was no adjustment for multiple testing, however a hierarchy approach to control for the Type-I error was used. If the 10mg was not successful, any analysis of the 5mg will be descriptive, and similarly for the next step for the 1mg.</p_value_desc>
            <method>Pairwise comparison based on ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.01</ci_lower_limit>
            <ci_upper_limit>-0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 1 mg vs. Placebo
Missing endpoints after 12 weeks of treatment were replaced using &quot;Last Observation Carried Forward&quot; (LOCF)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0055</p_value>
            <p_value_desc>There was no adjustment for multiple testing, however a hierarchy approach to control for the Type-I error was used. If the 10mg was not successful, any analysis of the 5mg will be descriptive, and similarly for the next step for the 1mg.</p_value_desc>
            <method>Pairwise comparison based on ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Placebo vs. Linagliptin 10 mg
Analysis additionally adjusted for previous anti-diabetic medication.
Missing endpoints after 12 weeks of treatment were replaced using Last Observation Carried Forward (LOCF).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Pairwise comparison based on ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5 mg vs. Placebo
Analysis additionally adjusted for previous anti-diabetic medication.
Missing endpoints after 12 weeks of treatment were replaced using “last observation carried forward” (LOCF).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Pairwise comparison based on ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.02</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 1 mg vs. Placebo
Analysis additionally adjusted for previous anti-diabetic medication.
Missing endpoints after 12 weeks of treatment were replaced using “last observation carried forward” (LOCF).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0049</p_value>
            <method>Pairwise comparison based on ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.66</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With HbA1c&lt;=7.0% at Week 12</title>
        <description>Descriptive calculation of Patients with HbA1c &lt;= 7.0% at Week 12.</description>
        <time_frame>week 12</time_frame>
        <population>This population includes the Full Analysis Set (FAS). Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 1 mg</title>
            <description>Patients randomized to receive treatment with Linagliptin 1 mg</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin 5 mg</title>
            <description>Patients randomized to receive treatment with Linagliptin 5 mg</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin 10 mg</title>
            <description>Patients randomized to receive treatment with Linagliptin 10 mg</description>
          </group>
          <group group_id="O5">
            <title>Glimepiride</title>
            <description>Patients randomized to receive treatment with Glimepiride</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With HbA1c&lt;=7.0% at Week 12</title>
          <description>Descriptive calculation of Patients with HbA1c &lt;= 7.0% at Week 12.</description>
          <population>This population includes the Full Analysis Set (FAS). Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="15.6"/>
                    <measurement group_id="O3" value="14.5"/>
                    <measurement group_id="O4" value="21.2"/>
                    <measurement group_id="O5" value="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 10 mg vs. Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0054</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>18.575</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.367</ci_lower_limit>
            <ci_upper_limit>145.781</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5 mg vs. Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0214</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>11.715</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.439</ci_lower_limit>
            <ci_upper_limit>95.351</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 1 mg vs. Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0167</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>12.776</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.586</ci_lower_limit>
            <ci_upper_limit>102.895</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Glimepiride vs. Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>31.360</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.063</ci_lower_limit>
            <ci_upper_limit>242.028</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Blood Plasma Glucose Level (FPG) Change From Baseline at Week 12</title>
        <description>This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>This population includes the FAS using the LOCF imputation, with the further restriction of patients with a baseline and post-baseline FPG value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomized to receive treatment with matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 1 mg</title>
            <description>Patients randomized to receive treatment with Linagliptin 1 mg</description>
          </group>
          <group group_id="O3">
            <title>Linagliptin 5 mg</title>
            <description>Patients randomized to receive treatment with Linagliptin 5 mg</description>
          </group>
          <group group_id="O4">
            <title>Linagliptin 10 mg</title>
            <description>Patients randomized to receive treatment with Linagliptin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Blood Plasma Glucose Level (FPG) Change From Baseline at Week 12</title>
          <description>This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and previous anti-diabetic medication.</description>
          <population>This population includes the FAS using the LOCF imputation, with the further restriction of patients with a baseline and post-baseline FPG value.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.63" spread="4.30"/>
                    <measurement group_id="O2" value="-5.32" spread="4.51"/>
                    <measurement group_id="O3" value="-21.29" spread="4.48"/>
                    <measurement group_id="O4" value="-15.87" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 10mg vs. Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Pairwise comparison based on ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-29.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-41.4</ci_lower_limit>
            <ci_upper_limit>-17.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 5mg vs. Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Pairwise comparison based on ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-34.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-47.0</ci_lower_limit>
            <ci_upper_limit>-22.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin 1 mg vs. Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <method>Pairwise comparison based on ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-18.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-31.0</ci_lower_limit>
            <ci_upper_limit>-6.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 Weeks + 30 Days</time_frame>
      <desc>MedDRA version 10.0 was used for reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients randomized to receive treatment with matching placebo</description>
        </group>
        <group group_id="E2">
          <title>Linagliptin 1 mg</title>
          <description>Patients randomized to receive treatment with Linagliptin 1 mg</description>
        </group>
        <group group_id="E3">
          <title>Linagliptin 5 mg</title>
          <description>Patients randomized to receive treatment with Linagliptin 5 mg</description>
        </group>
        <group group_id="E4">
          <title>Linagliptin 10 mg</title>
          <description>Patients randomized to receive treatment with Linagliptin 10 mg</description>
        </group>
        <group group_id="E5">
          <title>Glimepiride</title>
          <description>Patients randomized to receive treatment with Glimepiride</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

